Synopsis
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Topical
Solubilizers
API Stability Enhancers
Fillers, Diluents & Binders
Granulation
Emulsifying Agents
Taste Masking
Direct Compression
Chewable & Orodispersible Aids
Coating Systems & Additives
Thickeners and Stabilizers
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Surfactant & Foaming Agents
Controlled & Modified Release
Co-Processed Excipients
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
92
PharmaCompass offers a list of Sodium Hyaluronate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sodium Hyaluronate manufacturer or Sodium Hyaluronate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Hyaluronate manufacturer or Sodium Hyaluronate supplier.
A Sodium Hyaluronate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium Hyaluronate, including repackagers and relabelers. The FDA regulates Sodium Hyaluronate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium Hyaluronate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium Hyaluronate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Sodium Hyaluronate supplier is an individual or a company that provides Sodium Hyaluronate active pharmaceutical ingredient (API) or Sodium Hyaluronate finished formulations upon request. The Sodium Hyaluronate suppliers may include Sodium Hyaluronate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium Hyaluronate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Sodium Hyaluronate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium Hyaluronate active pharmaceutical ingredient (API) in detail. Different forms of Sodium Hyaluronate DMFs exist exist since differing nations have different regulations, such as Sodium Hyaluronate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium Hyaluronate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium Hyaluronate USDMF includes data on Sodium Hyaluronate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium Hyaluronate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium Hyaluronate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sodium Hyaluronate Drug Master File in Japan (Sodium Hyaluronate JDMF) empowers Sodium Hyaluronate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sodium Hyaluronate JDMF during the approval evaluation for pharmaceutical products. At the time of Sodium Hyaluronate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sodium Hyaluronate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Sodium Hyaluronate Drug Master File in Korea (Sodium Hyaluronate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Sodium Hyaluronate. The MFDS reviews the Sodium Hyaluronate KDMF as part of the drug registration process and uses the information provided in the Sodium Hyaluronate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Sodium Hyaluronate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Sodium Hyaluronate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Sodium Hyaluronate suppliers with KDMF on PharmaCompass.
A Sodium Hyaluronate CEP of the European Pharmacopoeia monograph is often referred to as a Sodium Hyaluronate Certificate of Suitability (COS). The purpose of a Sodium Hyaluronate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sodium Hyaluronate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sodium Hyaluronate to their clients by showing that a Sodium Hyaluronate CEP has been issued for it. The manufacturer submits a Sodium Hyaluronate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sodium Hyaluronate CEP holder for the record. Additionally, the data presented in the Sodium Hyaluronate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sodium Hyaluronate DMF.
A Sodium Hyaluronate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sodium Hyaluronate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sodium Hyaluronate suppliers with CEP (COS) on PharmaCompass.
A Sodium Hyaluronate written confirmation (Sodium Hyaluronate WC) is an official document issued by a regulatory agency to a Sodium Hyaluronate manufacturer, verifying that the manufacturing facility of a Sodium Hyaluronate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sodium Hyaluronate APIs or Sodium Hyaluronate finished pharmaceutical products to another nation, regulatory agencies frequently require a Sodium Hyaluronate WC (written confirmation) as part of the regulatory process.
click here to find a list of Sodium Hyaluronate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sodium Hyaluronate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sodium Hyaluronate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sodium Hyaluronate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sodium Hyaluronate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sodium Hyaluronate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sodium Hyaluronate suppliers with NDC on PharmaCompass.
Sodium Hyaluronate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium Hyaluronate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sodium Hyaluronate GMP manufacturer or Sodium Hyaluronate GMP API supplier for your needs.
A Sodium Hyaluronate CoA (Certificate of Analysis) is a formal document that attests to Sodium Hyaluronate's compliance with Sodium Hyaluronate specifications and serves as a tool for batch-level quality control.
Sodium Hyaluronate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium Hyaluronate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium Hyaluronate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium Hyaluronate EP), Sodium Hyaluronate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium Hyaluronate USP).
